Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Maverix Biomics Closes $6 Million Series A Round

Published: Tuesday, January 07, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Funds will be used to continue commercial momentum and rapidly expand usage of the Maverix Analytic Platform.

Maverix Biomics, Inc. announced that it has closed a $6 million Series A funding round. The company’s pioneering flagship offering, the Maverix Analytic Platform, simplifies complex big data analytics for life science researchers; integrating context-based data exploration, interactive visualization, secure data management, and affordable long-term storage in an easy-to-use cloud-based solution. 

The financing was led by one of Silicon Valley’s oldest and most prestigious venture capital firms, Asset Management Ventures, and two prominent Silicon Valley information technology investors, Andreas Bechtolsheim and Andrew Yang. Bechtolsheim was a co-founder of Sun Microsystems, Granite Systems, and Kealia, and is currently Chairman of the Board at Arista Networks. Perhaps most notably, Bechtolsheim was one of the original angel investors in Google in 1998. Yang was cofounder of Apache Design (now a division of ANSYS) and is currently an active entrepreneur and investor, with a portfolio including Anagram, CADMOS Design, and Mojave. 

At the close of the round, Louis G. Lange MD PhD, General Partner at Asset Management Ventures and Senior Advisor at Gilead Sciences, and Andrew Yang PhD, Vice President and General Manager of ANSYS, joined the Maverix board. The Series A funds will be used to continue commercial momentum and rapidly expand usage of the Maverix Analytic Platform, which has already gained market traction and is generating revenue from a number of influential researchers and scientists in pharmaceutical, molecular diagnostics, clinical, agricultural, and academic research settings. Maverix also recently announced a co-marketing alliance with Qiagen to streamline the interpretation of raw next-generation gene expression data into meaningful and actionable insights. 

“Maverix is a great example of a portfolio company where Asset Management can offer its expertise in both life sciences and information technology. We have been consistently impressed with the company's leadership, scientific, and software development expertise,” said Dr. Lange. “As high-throughput sequencing becomes a mainstream research and clinical technology, bioinformatics must move from the computer room directly into the hands of life scientists, creating a hundred-fold increase in potential customers that Maverix is uniquely poised to serve.” 

“I have been very impressed with the Maverix team and their ability to differentiate the Maverix Analytic Platform from other bioinformatics solutions,” said Dr. Yang. “The Maverix value proposition is appealing to scientists who lack computer programming skills and cannot or do not want to invest in the IT infrastructure necessary to process and understand the vast amounts of raw genomic data resulting from large sequencing projects. This market dynamic is analogous to my previous success in developing software solutions for the electronic design automation and semiconductor industries." 

“It’s both exciting and gratifying to have two pre-eminent investor groups from the life sciences and information technology arenas come together to back Maverix,” said Dave Mandelkern, Maverix co-founder and CEO. “We’ve already gained a significant amount of momentum, credibility and revenue in the marketplace and this round of funding is a huge endorsement of our vision as a leader in NGS gene expression analytics.” 

Researchers using the Maverix Analytic Platform experience a simple, collaborative user environment that allows them to upload their own data, initiate their own analyses, and put their results in context with other public and private data sources. Leveraging the power of proven, open source analytic tools that previously have been available only to bioinformatics experts, researchers are able to immediately perform analyses with reliable, scientifically recommended configurations, as validated and cited in peerreviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including the UCSC Genome Browser, the world’s most widely used genome browser. 

“UC Santa Cruz has been one of the leading centers for genomics research for over a decade. Maverix has really benefited from the talents of UCSC graduates, as they continue a tradition of creating tools and resources used around the world,” said Todd Lowe, Ph.D., Professor of Biomolecular Engineering at UC Santa Cruz, and co-founder of Maverix. “The company is building on this know-how to directly address the needs of a much broader audience of scientists new to NGS analytics, as well as those who want to scale up their analytics by orders of magnitude.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Probe Identifies Schizophrenia Genes That Stunt Brain Development
Scientists have isolated schizophrenia-related gene variants that change gene expression in the brain.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!